Butyrate inhibits inflammatory responses through NFκB inhibition: Implications for Crohn's disease

Gut

Volumn 47, Issue 3, 2000, Pages 397-403

  Segain, J P ^a   Galmiche, J P ^a   Raingeard De La Bletiere D ^a   Bourreille, A ^a   Leray, V ^a   Gervois, N ^a   Rosales, C ^b   Ferrier, L ^a   Bonnet, C ^a   Blottiere H M ^a  

^a INSERM   (France)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Butyrate; Crohn's disease; Cytokines; Inflammation; Nuclear factor kappa B

Indexed keywords

BUTYRIC ACID; ENEMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; ANIMALS; BLOTTING, WESTERN; BUTYRATES; CELLS, CULTURED; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NF-KAPPA B; PROSPECTIVE STUDIES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033863238     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.3.397     Document Type: Article

References (47)

1. 1 Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5-11S.
2. 2 Brynskov J, Nielsen OH, Ahnfelt-Ronne I, et al. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994;12:290-304.
3. 3 Plevy SE, Targan SR, Deem RL, et al. Increased mucosal TNF-α levels and numbers of TNF-α producing cells are unique to Crohn's disease mucosal inflammation. Gastroenterology 1995;106:A754.
4. 4 Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
5. 5 Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32: 913-17.
6. 6 Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
7. 7 Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9.
8. 8 Bouma G, Oudkerk Pool M, Scharenberg JG, et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100.
9. 9 Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113:1465-73.
10. 10 Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1996;8:872-7.
11. 11 Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
12. 12 Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
13. 13 Elliot MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
14. 14 Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42:477-84.
15. 15 Rogler G, Brand K, Vogl D, et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-69.
16. 16 Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2: 998-1004.
17. 17 Baldwin AS Jr. The NF-kappa B and 1 kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14: 649-83.
18. 18 Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut 1994;35(suppl 1):S35-8.
19. 19 Butzner JD, Parmar R, Bell CJ, et al. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996;38:568-73.
20. 20 Roediger WEW. The colonic epithelium in ulcerative colitis: an energy-deficiency disease. Lancet 1980;2:712-15.
21. 21 Den Hond E, Hiele M, Evenepoel P, et al. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology 1998; 115:584-90.
22. 22 Böhmig GA, Krieger PM, Saemann MD, et al. n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 1997;92:234-43.
23. 23 Gilbert KM, Weigle WO. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 1993;151:1245-54.
24. 24 Siavoshian S, Blottiere HM, Bentouimou N, et al. Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells. Eur J Clin Invest 1996;26:803-10.
25. 25 Bull DM, Bookman MA. Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest 1977;59:966-74.
26. 26 Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Method 1986;95:99-105.
27. 27 Rosales C, Juliano R. Integrin signaling to NF-kappa B in monocytic leukemia cells is blocked by activated oncogenes. Cancer Res 1996;56:2302-5.
28. 28 Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
29. 29 Barbier M, Cherbut C, Aube AC, et al. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 1998;43:783-90.
30. 30 Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
31. 31 Kruh J, Tichonicky L, Defer N. Effect of butyrate on gene expression. In: Binder HJ, Cummings J, Soergel KH, eds. Short chain fatty acids. Dordrecht: Kluwer Academic, 1994: 135-47.
32. 32 Ohno Y, Lee J, Fusunyan RD, et al. Macrophage inflammatory protein-2: chromosomal regulation in rat small intestinal epithelial cells. Proc Natl Acad Sci USA 1997;94:10279-84.
33. 33 Xing JH, Cherbut C, Joubert M, et al. Short chain fatty acid propionate and the role of β-oxidation of butyrate in rat experimental colitis. Gastroenterology 1998;114:A1118.
34. 34 Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39:684-9.
35. 35 Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
36. 36 Baldassano RN, Schreiber S, Johnston RB Jr, et al. Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology 1993;105:60-6.
37. 37 May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998;19:80-8.
38. 38 Wu GD, Huang N, Wen X, et al. High-level expression of I kappa B-beta in the surface epithelium of the colon: in vitro evidence for an immunomodulatory role. J Leukoc Biol 1999;66:1049-56.
39. 39 Andoh A, Fujiyama Y, Hata K, et al. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999;118:23-9.
40. 40 Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-9.
41. 41 Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270: 286-90.
42. 42 Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor α and interleukin-1β in relapse of Crohn's disease. Lancet 1999;353:459-61.
43. 43 Mackay F, Browning JL, Lawton P, et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998;115:1464-75.
44. 44 Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992;4:327-32.
45. 45 Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
46. 46 Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81-6.
47. 47 Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-9.